# A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

> **NCT06598462** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Uniquity One (UNI)** · enrollment: 184 (actual)

## Conditions studied

- Eosinophilic Esophagitis (EoE)

## Interventions

- **BIOLOGICAL:** Solrikitug Low Dose
- **BIOLOGICAL:** Solrikitug Mid Dose
- **BIOLOGICAL:** Solrikitug High Dose
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06598462
- **Lead sponsor:** Uniquity One (UNI)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-16
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-08-31
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06598462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06598462, "A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06598462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*